Clinical

Dataset Information

0

Phase IB clinical study on the tolerance, safety and efficacy of darafenib, trametinib combined with irinotecan and cetuximab in advanced colorectal cancer with BRAF mutation

ABSTRACT: Interventions: experimental group:Darafenitumertinib plus iritiniconcetuximab Primary outcome(s): Maximum tolerated dose Study Design: Cross-sectional

DISEASE(S): Colorectal Cancer

PROVIDER: 47501 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
| S-EPMC4669588 | biostudies-literature
Unknown Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.
| S-EPMC7446525 | biostudies-literature
Unknown Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report.
| S-EPMC8474392 | biostudies-literature
Unknown INNV-30. RESPONSE WITH COMBINED DABRAFENIB AND TRAMETINIB AFTER BRAF INHIBITOR FAILURE IN BRAF-MUTATED GLIOBLASTOMA: A CASE REPORT
| S-EPMC6847586 | biostudies-literature
Unknown Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
| S-EPMC5006894 | biostudies-literature
Unknown Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
| S-EPMC4226803 | biostudies-literature
Unknown Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
| S-EPMC10163281 | biostudies-literature
Unknown RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.
| S-EPMC9175793 | biostudies-literature
Unknown Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
| S-EPMC3701070 | biostudies-literature
Unknown Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
| S-EPMC10466457 | biostudies-literature